1. Sensitive determination of prostate-specific antigen with graphene quantum dot-based fluorescence aptasensor using few-layer V 2 CT x MXene as quencher.
- Author
-
Zhu T, Tang Q, Zeng Y, Chen S, Yang Y, Wang H, Chen J, Guo L, and Li L
- Subjects
- Male, Humans, Prostate-Specific Antigen, Fluorescence, Tomography, X-Ray Computed, Limit of Detection, Quantum Dots chemistry, Graphite chemistry, Aptamers, Nucleotide chemistry, Biosensing Techniques methods
- Abstract
A novel fluorescence aptasensor of prostate-specific antigen (PSA) was established using few-layer vanadium carbide (FL-V
2 CTx ) nanosheet as a quencher. First, FL-V2 CTx was prepared by the delamination of multi-layer V2 CTx (ML-V2 CTx ) with tetramethylammonium hydroxide. The aptamer-carboxyl graphene quantum dots (CGQDs) probe was prepared by combining the aminated PSA aptamer and CGQDs. Then, the aptamer-CGQDs were absorbed onto the surface of FL-V2 CTx by hydrogen bond interaction, which led to the decrease in fluorescence of aptamer-CGQDs due to photoinduced energy transfer. After addition of PSA, PSA-aptamer-CGQDs complex was released from FL-V2 CTx . The fluorescence intensity of aptamer-CGQDs-FL-V2 CTx with PSA was higher than that without PSA. The FL-V2 CTx -based fluorescence aptasensor provided a PSA detection linear range from 0.1 to 20 ng mL-1 with detection limit of 0.03 ng mL-1 . The ΔF value of fluorescence intensities for aptamer-CGQDs-FL-V2 CTx with and without PSA was 5.6, 3.7, 7.7, and 5.4 times of ML-V2 CTx , few-layer titanium carbide (FL-Ti3 C2 Tx ), ML-Ti3 C2 Tx and graphene oxide aptasensors, respectively, indicating the advantage of FL-V2 CTx . The aptasensor had high selectivity for PSA detection compared with some proteins and tumor markers. This proposed method had convenience and high sensitivity for PSA determination. The determination results of PSA in human serum samples using the aptasensor were consistent with those by chemiluminescent immunoanalysis. The fluorescence aptasensor can be successfully applied for PSA determination in serum samples of prostate cancer patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF